Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.5552W HIGH $54.97
Volume
215.73 K
Value Traded
169.42 M
Short % Float
16.12%
Days to Cover
2.3
-10.22%Week
-29.69%1 Month
-92.07%3 Month
-90.82%6 Month
+64.52%5 Year
+64.52%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
163.67 M
EPS (TTM)
-2.15
P/E Ratio
-
Ent. Value
-105.94 M
Total Shares
45.21 M
Float Shares
23.56 M
Insiders
47.89%
Institutions
65.46%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SION Catalyst Timeline
Dated clinical, regulatory and corporate events for Sionna Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sionna Therapeutics, Inc.
99Total events
7Upcoming
21Tier-1 (high impact)
2025 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Oral PresentationSION-719Presentation
Oral presentation of post hoc PreciSION CF analyses of SION-719 at NACFC 2026
cystic fibrosissource ↗
●Poster PresentationSION-451Presentation
Poster 295 on NBD1 stabilizers SION-451 and SION-719 in combination with other CFTR modulators at NACFC 2026
cystic fibrosissource ↗
●Poster PresentationSION-719Presentation
Poster 295 on NBD1 stabilizers SION-451 and SION-719 in combination with other CFTR modulators in CFHBE cells at NACFC 2026
cystic fibrosissource ↗
▲Topline ReadoutSION-719Clinical Data
Post hoc analysis of SION-719 PreciSION CF Phase 2a shows up to -8.6 mmol/L placebo-adjusted sweat chloride reduction in subset
cystic fibrosissource ↗
▼Restructuring LayoffsCorporate
Board approved approximately 46% workforce reduction and cost-saving measures
▼Program DiscontinuationSION-719Corporate
Discontinuation of investment in SION-719 as an add-on to standard of care
cystic fibrosissource ↗
▲Topline ReadoutSION-451Clinical Data
Phase 1 topline results for SION-451-based dual combinations announced
cystic fibrosissource ↗
▼Program DiscontinuationSION-719Corporate
Sionna does not plan to advance SION-719 as add-on to standard of care
cystic fibrosissource ↗
●Oral PresentationSION-719Presentation
Presentation at 16th Australasian Cystic Fibrosis Conference
cystic fibrosissource ↗
●Oral PresentationSION-451Presentation
Presentation at 16th Australasian Cystic Fibrosis Conference
cystic fibrosissource ↗
▼Topline ReadoutSION-719Clinical Data
Topline data from Phase 2a PreciSION CF trial of SION-719
cystic fibrosissource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
cystic fibrosissource ↗
◆Oral PresentationSION-719Presentation
Oral ePoster presentation of encore data from Phase 1 studies of SION-719 and SION-451 at ECFS 2026
cystic fibrosissource ↗
◆Oral PresentationPresentation
Jefferies Global Healthcare Conference presentation
cystic fibrosissource ↗
◆Topline ReadoutSION-719Clinical Data
Topline data from Phase 2a POC trial for SION-719
cystic fibrosissource ↗
◆Topline ReadoutSION-451Clinical Data
Topline data from Phase 1 dual combination trial for SION-451
cystic fibrosissource ↗
●Oral PresentationSION-719Presentation
Presented encore data at 49th European Cystic Fibrosis Conference
cystic fibrosissource ↗
●Oral PresentationSION-451Presentation
Presented encore data at 49th European Cystic Fibrosis Conference
cystic fibrosissource ↗
◆Oral PresentationPresentation
Fireside chat at 2026 RBC Capital Markets Global Healthcare Conference
cystic fibrosissource ↗
▲Enrollment CompleteSION-719Trial
Completed enrollment in PreciSION CF Phase 2a trial evaluating SION-719 added to standard of care
cystic fibrosissource ↗
◆R&D DayPresentation
Management to participate in one-on-one investor meetings at Raymond James 2026 Biotech Innovation Symposium
◆Topline ReadoutSION-719Clinical Data
Topline data from PreciSION CF Phase 2a trial expected in summer 2026
cystic fibrosissource ↗
◆Topline ReadoutSION-451Clinical Data
Topline data from Phase 1 dual combination trial anticipated
cystic fibrosissource ↗
▲Enrollment CompleteSION-719Trial
Completed enrollment in PreciSION CF Phase 2a trial
cystic fibrosissource ↗
◆Topline ReadoutClinical Data
Topline data from ongoing trials expected in mid-2026
cystic fibrosissource ↗
●Quarterly UpdateCorporate
Sionna ended Q2 2026 with approximately $268.3 million in cash, cash equivalents, and marketable securities
◆Oral PresentationPresentation
Management participation in upcoming investor conferences
cystic fibrosissource ↗
◆Oral PresentationPresentation
Management to present at Guggenheim Securities Emerging Outlook: Biotech Summit 2026
cystic fibrosissource ↗
◆Oral PresentationPresentation
Sionna management presentation at 44th Annual J.P. Morgan Healthcare Conference
cystic fibrosissource ↗
◆Oral PresentationPresentation
Management to participate in fireside chats at upcoming December investor conferences
cystic fibrosissource ↗
◆Oral PresentationPresentation
Management to participate in fireside chats at upcoming November investor conferences
cystic fibrosissource ↗
◆Poster PresentationSION-719Presentation
Safety, tolerability, and pharmacokinetics of SION-719 and SION-451 from two phase 1 first-in-human studies
cystic fibrosissource ↗
◆Poster PresentationSION-451Presentation
Safety, tolerability, and pharmacokinetics of SION-719 and SION-451 from two phase 1 first-in-human studies
cystic fibrosissource ↗
◆Poster PresentationPresentation
Small molecule stabilizers of CFTR NBD1 can extend the half-life of the apical glycoform of F508del-CFTR to match that of wild-type CFTR
cystic fibrosissource ↗
▲Oral PresentationSION-719Presentation
Phase 1 data of SION-719 presented at NACFC 2025
cystic fibrosissource ↗
▲Oral PresentationSION-451Presentation
Phase 1 data of SION-451 presented at NACFC 2025
cystic fibrosissource ↗
▲Poster PresentationSION-719Presentation
Preclinical data on NBD1 stabilizer impact on F508del-CFTR half-life presented at NACFC 2025
cystic fibrosissource ↗
▲Poster PresentationSION-451Presentation
Preclinical data on NBD1 stabilizer impact on F508del-CFTR half-life presented at NACFC 2025
cystic fibrosissource ↗
▲Trial InitiationSION-719Trial
Initiation of PreciSION CF Phase 2a trial evaluating SION-719 added to standard of care
cystic fibrosissource ↗
▲Trial InitiationSION-719Trial
Initiation of PreciSION CF Phase 2a proof-of-concept trial with SION-719
cystic fibrosissource ↗
▲Trial InitiationSION-451Trial
Initiated Phase 1 trial of SION-451 in proprietary dual combinations with SION-2222 and SION-109
cystic fibrosissource ↗
▲Oral PresentationSION-719Presentation
Oral presentation of Phase 1 data for SION-719 and SION-451 at NACFC 2025
cystic fibrosissource ↗
▲Poster PresentationSION-719Presentation
Poster presentation of preclinical data for SION-719 and SION-451 at NACFC 2025
cystic fibrosissource ↗
Past FDA Catalysts and PDUFA Decisions
How SION actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-31 | SION-451 (dual combinations with SION-2222 and SION-109) | Phase 1 topline data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 60%
Micro Cap(rank 395 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SION-719 Small moleculeCompletedNCT07108153 | Cystic Fibrosis (CF) | Phase 2 | COMPLETED | 15 | Jun 25, 2026 | ||||||
| SION-451 Small moleculeCompletedNCT07035990 | Cystic Fibrosis (CF) | Phase 1 | COMPLETED | 120 | Mar 23, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every SION program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.Director, 10% Owner | Sell | -3,415,011 3,482,612 held | $6.32 | 09/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SION
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 3.8 % (-9.5 %) | 435.72 M | 9.91 M |
SION Institutional Ownership Trends
SION Short Interest
Shares sold short, counted twice a month.
16.12%
Short % of Float
of tradable shares sold short
3.8M
Shares Sold Short
-4.2% vs prior count
2.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.6M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SION ranks across every disease it competes in
Competitive Position is a premium feature
See how SION ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSION News
SIONSionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Sionna Therapeutics announced the presentation of data at the 2026 North American Cystic Fibrosis Conference, highlighting advancements in their CF drug candidates. The company will present findings from the PreciSION CF trial and new preclinical data on NBD1 stabilizers. Despite not meeting key endpoints in the trial, the data supports further development of SION-451 and SION-2222.
Read more →SION▼ -16.7%on this news· ran to -28% by day 3
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Sionna Therapeutics announced plans to advance its dual combination therapy, SION-451 + SION-2222, into a Phase 2a proof-of-concept trial following a favorable post hoc analysis of the SION-719 PreciSION CF trial. The trial is set to begin in Q1 2027, despite a recent workforce reduction aimed at extending the company's cash runway. The analysis revealed potential factors affecting previous trial outcomes, reinforcing the need for new cystic fibrosis treatments.
Read more →SION▼ -91.2%on this news
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
Sionna Therapeutics reported disappointing results from its Phase 2a trial of SION-719, which failed to achieve the key endpoint of sweat chloride reduction. The company will not pursue SION-719 as an add-on treatment. However, the Phase 1 trial of SION-451 showed positive safety and tolerability results, leading to further evaluations. Sionna ended Q2 with a strong cash position of $268.3 million.
Read more →SIONSionna Therapeutics Reports Second Quarter 2026 Financial Results
Sionna Therapeutics reported its Q2 2026 financial results, highlighting progress in its clinical trials for cystic fibrosis treatments. The company is on track to release topline data for both its Phase 2a and Phase 1 trials this summer. Despite a net loss of $29.9 million, Sionna maintains a strong cash position of $268.3 million, expected to sustain operations until 2028.
Read more →SIONSionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
Sionna Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences in June 2026. The events include a presentation at the Jefferies Global Healthcare Conference and a fireside chat at the Goldman Sachs Global Healthcare Conference. Sionna aims to revolutionize cystic fibrosis treatment through novel therapies targeting the CFTR protein.
Read more →SION▲ +5.3%on this news
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Sionna Therapeutics will participate in the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026. The event will include a fireside chat with management, highlighting the company's efforts to transform cystic fibrosis treatment. Sionna aims to develop novel therapies that enhance CFTR protein function, focusing on the F508del mutation.
Read more →SION▼ -10.9%on this newsshared move
Sionna Therapeutics Reports First Quarter 2026 Financial Results
Sionna Therapeutics has reported its first-quarter financial results for 2026, highlighting the completion of enrollment in the Phase 2a trial for SION-719, which is evaluating cystic fibrosis treatment. The company maintains a strong cash position of approximately $289.9 million, expected to sustain operations through 2028. However, Sionna recorded a net loss of $26.8 million, an increase from the previous year, alongside rising research and development expenses. Topline data from ongoing trials is anticipated for summer 2026.
Read more →SIONSionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Sionna Therapeutics has completed enrollment in its PreciSION CF Phase 2a trial, evaluating SION-719, an NBD1 stabilizer, alongside the standard care Trikafta in cystic fibrosis patients. This trial aims to assess the safety and pharmacokinetics of SION-719 and its impact on CFTR function. Data from the trial is expected in summer 2026.
Read more →SIONSionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
Sionna Therapeutics, a clinical-stage biopharmaceutical company, will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026. The company focuses on developing novel therapies aimed at normalizing CFTR protein function to improve treatment outcomes for cystic fibrosis patients. Sionna's innovative approach includes small molecules targeting the F508del mutation and complementary CFTR modulators.
Read more →SION▼ -7.2%on this news
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Sionna Therapeutics reported its financial results for Q4 and full year 2025, highlighting ongoing clinical trials for its NBD1 stabilizers SION-719 and SION-451. The company maintains a robust cash position of approximately $310.3 million, expected to support operations until 2028. Topline data from ongoing trials is anticipated in mid-2026, marking significant progress in their pipeline for cystic fibrosis treatments.
Read more →SIONSionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
Sionna Therapeutics, a clinical-stage biopharmaceutical company, will participate in upcoming investor conferences. The company focuses on developing novel therapies for cystic fibrosis by targeting the CFTR protein. Their approach aims to improve the quality of life for patients by correcting genetic defects. Live webcasts of the presentations will be available on their website.
Read more →SION▼ -7.1%on this news· ran to -21% by day 1
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Sionna Therapeutics will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The company aims to revolutionize cystic fibrosis treatment by developing novel medicines that normalize CFTR protein function. Their approach focuses on correcting defects caused by the F508del genetic mutation and improving patient quality of life.
Read more →SIONSionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sionna Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company focuses on developing novel medicines to enhance the function of the CFTR protein for cystic fibrosis treatment. A live webcast of the presentation will be available on their Investor Relations website.
Read more →SIONSionna Therapeutics to Participate in Upcoming December Investor Conferences
Sionna Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences. The company aims to revolutionize cystic fibrosis treatment by developing novel medicines that stabilize the CFTR protein. Live webcasts of the presentations will be available on their Investor Relations website, ensuring accessibility for stakeholders.
Read more →SIONSionna Therapeutics Reports Third Quarter 2025 Financial Results
Sionna Therapeutics reported a net loss of $20.3 million for the third quarter of 2025. The company initiated Phase 2a and Phase 1 trials for its cystic fibrosis candidates SION-719 and SION-451. It ended the quarter with $325.0 million in cash and cash equivalents. Management expects this balance to fund operations through 2028.
Read more →SIONSionna Therapeutics to Participate in Upcoming November Investor Conferences
Sionna Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences. The company aims to revolutionize cystic fibrosis treatment by developing novel medicines targeting the CFTR protein. Live webcasts of the presentations will be available on their Investor Relations website, allowing for broader access to their developments.
Read more →SIONSionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
Sionna Therapeutics presented promising Phase 1 data for its NBD1 stabilizers, SION-719 and SION-451, at the 2025 North American Cystic Fibrosis Conference. The data indicated that both compounds were well tolerated and met pharmacokinetic targets. Additionally, new preclinical findings demonstrated that these stabilizers could restore the half-life of F508del-CFTR to levels comparable to wild-type CFTR. The company is advancing its clinical programs with expectations for further results in mid-2026.
Read more →SION▲ +32%on this newsshared move
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
Sionna Therapeutics has initiated the PreciSION CF Phase 2a trial to evaluate SION-719, a novel NBD1 stabilizer, in cystic fibrosis patients. This trial aims to assess the safety and efficacy of SION-719 when added to the current standard of care, Trikafta. Topline results are anticipated by mid-2026, potentially marking a significant advancement in CF treatment.
Read more →SIONSionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
Sionna Therapeutics will present data at the 2025 North American Cystic Fibrosis Conference in Seattle. The presentations will focus on the safety and pharmacokinetics of their novel NBD1 stabilizers, SION-719 and SION-451, from phase 1 studies. The conference will take place from October 22-25, 2025, showcasing advancements in cystic fibrosis treatment.
Read more →SION▼ -9.9%on this news
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
Sionna Therapeutics has appointed Caroline Stark Beer as its new Chief Business Officer. With over 20 years of experience in the life sciences, Beer is expected to enhance the company's corporate development efforts. Sionna focuses on developing innovative therapies for cystic fibrosis, aiming to improve patient outcomes significantly.
Read more →About Sionna Therapeutics, Inc.
Headquarters21 HICKORY DRIVE, SUITE 500, WALTHAM, MA, 02451
BIOPHARMAWATCH ELITE PLUS
Trade the next SION catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime